{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:03:00Z","timestamp":1747184580573,"version":"3.40.5"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate whether low\u2010dose belantamab mafodotin (B\u2010MAF) dosing results in lower toxicity and better overall outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively evaluated nine consecutive patients treated with low\u2010dose (1.9\u2009mg\/kg) B\u2010MAF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age was 70\u2009years. Most patients were penta\u2010refractory. Ocular toxicity was observed in 77.7%. Adverse events resulting in treatment delays were recorded in 9 out of 124\u2009cycles being given. Overall response rate was 66% (6\/9), and all responding patients achieved very good partial response or better. Within a median follow\u2010up of 12 (range 0.5\u201313.8) months, median progression\u2010free survival and overall survival were 14 (CI95% 6\u201322) and 20 (95%CI 0\u201341) months, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Low\u2010dose B\u2010MAF regimen showed high\u2010efficacy and low\u2010toxicity profile.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14120","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T14:29:26Z","timestamp":1698330566000},"page":"367-370","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment with low\u2010dose, single\u2010agent belantamab mafodotin is safe and provides long\u2010term responses in heavily pretreated multiple myeloma patients"],"prefix":"10.1111","volume":"112","author":[{"given":"Irit","family":"Avivi","sequence":"first","affiliation":[{"name":"Department of Haematology Tel\u2010Aviv Sourasky Medical Center  Tel\u2010Aviv Israel"},{"name":"Sackler Faculty of Medicine Tel\u2010Aviv University  Tel\u2010Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3741-689X","authenticated-orcid":false,"given":"Tamir","family":"Shragai","sequence":"additional","affiliation":[{"name":"Department of Haematology Tel\u2010Aviv Sourasky Medical Center  Tel\u2010Aviv Israel"},{"name":"Sackler Faculty of Medicine Tel\u2010Aviv University  Tel\u2010Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0212-2135","authenticated-orcid":false,"given":"Efrat","family":"Luttwak","sequence":"additional","affiliation":[{"name":"Department of Haematology Tel\u2010Aviv Sourasky Medical Center  Tel\u2010Aviv Israel"},{"name":"Sackler Faculty of Medicine Tel\u2010Aviv University  Tel\u2010Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Trestman","sequence":"additional","affiliation":[{"name":"Department of Haematology Tel\u2010Aviv Sourasky Medical Center  Tel\u2010Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael C.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Haematology Tel\u2010Aviv Sourasky Medical Center  Tel\u2010Aviv Israel"},{"name":"Sackler Faculty of Medicine Tel\u2010Aviv University  Tel\u2010Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_2_9_5_1","article-title":"Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: results of the compassionate use or the expanded access program in Spain","volume":"15","author":"Rubia J","year":"2023","journal-title":"Cancers"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18479"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","unstructured":"BecnelM FerreriCJ FengL et al.Retrospective single\u2010center real\u2010world experience of belantamab mafodotin in relapsed\/refractory multiple myeloma.2022;40(suppl 16):8060. doi:10.1200\/JCO.2022.40.16_suppl.8060","DOI":"10.1200\/JCO.2022.40.16_suppl.8060"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00592-3"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149791"},{"key":"e_1_2_9_10_1","unstructured":"National Cancer Institute.Common terminology criteria for adverse events (CTCAE) v5.0.2017. Accessed March 22 2022https:\/\/www.meddra.org\/"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152241"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1269"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000334"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411829"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147101"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T02:26:10Z","timestamp":1708050370000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/ejh.14120"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14120","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"2023-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}